Karolinska Development’s portfolio company receives approval to initiate a clinical Phase 1b trial with sevuparin in the Netherlands
STOCKHOLM, SWEDEN – November 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Modus Therapeutics has received approval from the regulatory authorities in the Netherlands to carry out a clinical Phase 1b-study with sevuparin, a potential new treatment of sepsis/septic shock.
Sevuparin is an innovative drug candidate based on a polysaccharide with the potential of limiting vascular injury and plasma leakage in patients suffering from sepsis/septic shock or other medical conditions involving systemic inflammation.
The aim of the planned randomized, placebo-controlled Phase 1b-study is to investigate the effect of intravenously administrered sevuparin in dermal and systemic lipopolysaccharide-induced (LPS) inflammation in healthy individuals. The study will also evaluate sevuparin’s safety profile in combination with a standard of care prophylactic, anticoagulant heparin treatment. The study is designed using a well-established and recognized model that is utilized to mimic the early states of septic shock. Modus Therapeutics will conduct the study in collaboration with the Center for Human Drug Research (CHDR) in Leiden, the Netherlands, which is an experienced clinical research actor carrying an extensive expertise in inflammatory diseases and clinical studies.
“The regulatory go-ahead to start the Phase 1b study with sevuparin constitutes an important step forward for Modus Therapeutics. Sepsis/septic chock continues to pose a major challenge, due to its high annual mortality rate across the world there is a substantial need for new and effective treatments. We look forward to take part of the study results and to follow Modus Therapeutics’ continued development efforts", comments Viktor Drvota, CEO of Karolinska Development.
Karolinska Development's direct ownership interest, and indirect ownership interest via KDev Investment, in Modus Therapeutics amounts to 38% and 17%, respectively.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons8.5.2024 17:31:01 CEST | Press release
Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar2 Reason for the notificationa)Position/statusExecutive Vice Presidentb)Initial notification/AmendmentInitial notification3 Details of the issuera)NameNovo Nordisk A/Sb)LEI549300DAQ1CVT6CXN342
Treasury Bill Auction Announcement - RIKV 24 0717 - RIKV 24 11208.5.2024 17:31:00 CEST | Press release
SeriesRIKV 24 0717RIKV 24 1120ISINIS0000036267IS0000036366Maturity Date07/17/202411/20/2024Auction Date05/13/202405/13/2024Settlement Date05/15/202405/15/2024 On the Auction Date, between 10:30 am and 11:00 am, the Government Debt Management will auction Treasury bills in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Payments for the Treasury bills must be received by the Central Bank before 14:00 on the Settlement Date and the Bills will be delivered in electronic form on the same day. Further reference is made to the General Terms of Icelandic Treasury bills and General Terms of Auction for Treasury bills on the Government Debt Management website. For additional information please contact Magnús Freyr Hrafnsson, Government Debt Management, at +354 569 9679.
Valoe Postpones Its Annual General Meeting8.5.2024 17:20:00 CEST | Press release
Valoe Corporation Stock Exchange Release 8 May 2024 at 18.20 Finnish time Valoe Corporation’s (the “Company”) Board of Directors has resolved to postpone the Annual General Meeting of the Company to a date to be announced later due to the restructuring proceedings. A draft of Valoe's restructuring programme is expected to be completed by 14 June 2024. The Annual General Meeting will be held by the end of June 2024. As previously disclosed, the Annual General Meeting was scheduled to take place on 31 May 2024. The Board of Directors of Valoe will convene the Annual General Meeting at a later date. In Mikkeli, 8 May 2024 Valoe Corporation Board of Directors For more information: Iikka Savisalo President and CEO, Valoe Corporation Tel. +358 40 521 6082, email: iikka.savisalo@valoe.com Distribution: NASDAQ OMX, Helsinki Main media www.valoe.com Valoe Corporation designs, manufacturers, and sells solar power application projects, especially for vehicles and electronics. Valoe’s applications
Kvika – Méllon hs: Uppgreiðsla skuldabréfs8.5.2024 17:09:03 CEST | Press release
Með vísan í skilmála og verðbréfalýsingu MELLON151229 hefur útgefandi ákveðið að nýta sér heimild til að greiða upp skuldabréfið á næsta vaxtagjalddaga sem er þann 15. júní næstkomandi. Sjóðurinn mun því þriðjudaginn 18. júní 2024 greiða upp lánið. Greiðslan er tilkomin vegna afborgana af og uppgreiðslu á skuldabréfum í eigu sjóðsins síðustu vikur og mánuði. Nánari upplýsingar veitir Kvika eignastýring hf. sem er rekstraraðili útgefanda.
Arcadis' shareholders appoint board members and approve dividend8.5.2024 17:05:00 CEST | Press release
Arcadis 2024 Annual General Meeting Arcadis' shareholders appoint board members and approve dividend Virginie Duperat-Vergne reappointed as Chief Financial Officer (CFO) for an additional four-year termDeanna Goodwin reappointed to the Arcadis Supervisory Board for a an additional two-year termShareholders approved the company's dividend proposal of €0.85 per ordinary share Amsterdam, 8 May 2024 – Arcadis (EURONEXT: ARCAD), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, confirms that all resolutions that were brought up for vote were adopted during its annual General Meeting earlier today. Virginie Duperat-Vergne was reappointed as Chief Financial Officer (CFO) of Arcadis N.V. for an additional period of four years. She will continue to be a member of the Executive Board and member of the Arcadis Executive Leadership Team. Ms. Duperat joined Arcadis in 2020 and has been serving as the CFO since